318 related articles for article (PubMed ID: 33918043)
1. Physiological Imaging Methods for Evaluating Response to Immunotherapies in Glioblastomas.
Chawla S; Shehu V; Gupta PK; Nath K; Poptani H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918043
[TBL] [Abstract][Full Text] [Related]
2. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
Front Immunol; 2021; 12():790674. PubMed ID: 34899760
[TBL] [Abstract][Full Text] [Related]
3. New Immunotherapeutic Approaches for Glioblastoma.
Vázquez Cervantes GI; González Esquivel DF; Gómez-Manzo S; Pineda B; Pérez de la Cruz V
J Immunol Res; 2021; 2021():3412906. PubMed ID: 34557553
[TBL] [Abstract][Full Text] [Related]
4. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
5. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
[TBL] [Abstract][Full Text] [Related]
6. Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
de Godoy LL; Chawla S; Brem S; Mohan S
Clin Cancer Res; 2023 Jul; 29(14):2588-2592. PubMed ID: 37227179
[TBL] [Abstract][Full Text] [Related]
7. State of the Art Treatment and Surveillance Imaging of Glioblastomas.
Margiewicz S; Cordova C; Chi AS; Jain R
Semin Roentgenol; 2018 Jan; 53(1):23-36. PubMed ID: 29405952
[No Abstract] [Full Text] [Related]
8. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.
Curtin JF; King GD; Candolfi M; Greeno RB; Kroeger KM; Lowenstein PR; Castro MG
Curr Top Med Chem; 2005; 5(12):1151-70. PubMed ID: 16248789
[TBL] [Abstract][Full Text] [Related]
9. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
10. Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.
Gonçalves FG; Chawla S; Mohan S
J Magn Reson Imaging; 2020 Oct; 52(4):978-997. PubMed ID: 32190946
[TBL] [Abstract][Full Text] [Related]
11. Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI.
Park JE; Kim HS; Jo Y; Yoo RE; Choi SH; Nam SJ; Kim JH
Sci Rep; 2020 Mar; 10(1):4250. PubMed ID: 32144360
[TBL] [Abstract][Full Text] [Related]
12. Neuroimaging: diagnosis and response assessment in glioblastoma.
Clarke JL; Chang SM
Cancer J; 2012; 18(1):26-31. PubMed ID: 22290254
[TBL] [Abstract][Full Text] [Related]
13. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
14. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
Shiroishi MS; Boxerman JL; Pope WB
Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
[TBL] [Abstract][Full Text] [Related]
15. Management of Glioblastoma, Present and Future.
Oberheim Bush NA; Hervey-Jumper SL; Berger MS
World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
[TBL] [Abstract][Full Text] [Related]
16. Immunoengineering in glioblastoma imaging and therapy.
Zanganeh S; Georgala P; Corbo C; Arabi L; Ho JQ; Javdani N; Sepand MR; Cruickshank K; Campesato LF; Weng CH; Hemayat S; Andreou C; Alvim R; Hutter G; Rafat M; Mahmoudi M
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Nov; 11(6):e1575. PubMed ID: 31407522
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.
Verduin M; Compter I; Steijvers D; Postma AA; Eekers DBP; Anten MM; Ackermans L; Ter Laan M; Leijenaar RTH; van de Weijer T; Tjan-Heijnen VCG; Hoeben A; Vooijs M
Dis Markers; 2018; 2018():2908609. PubMed ID: 29581794
[TBL] [Abstract][Full Text] [Related]
18. Perfusion MRI-Based Fractional Tumor Burden Differentiates between Tumor and Treatment Effect in Recurrent Glioblastomas and Informs Clinical Decision-Making.
Iv M; Liu X; Lavezo J; Gentles AJ; Ghanem R; Lummus S; Born DE; Soltys SG; Nagpal S; Thomas R; Recht L; Fischbein N
AJNR Am J Neuroradiol; 2019 Oct; 40(10):1649-1657. PubMed ID: 31515215
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
20. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
